Results of this preplanned interim analysis demonstrated significantly improved DFS with adjuvant atezolizumab in patients with stage II-IIIA NSCLC, particularly for individuals with PD-L1–positive tumors.
On-demand webcast on biomarker-driven care for patients with NSCLC, from Clinical Care Options (CCO)
Downloadable slides for oncologists, pharmacists, and nurses: Immunotherapy and chemotherapy for extensive-stage SCLC from Clinical Care Options (CCO)
On-demand webcast on HER2, HER3, and TROP2 antibody-drug conjugates in breast, gastrointestinal, and lung cancers, from Clinical Care Options (CCO)
Downloadable summary slideset of key takeaways from a live symposium for nurses on management of EGFR ex20ins+ advanced NSCLC, from Clinical Care Options (CCO)